<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078088</url>
  </required_header>
  <id_info>
    <org_study_id>201608805</org_study_id>
    <nct_id>NCT03078088</nct_id>
  </id_info>
  <brief_title>Airway Alkalinization and Nasal Colonization</brief_title>
  <official_title>Airway Alkalinization and Nasal Colonization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a randomized, cross-over study of THAM followed by saline or saline
      followed by THAM in human non-CF and CF subjects to assess nasal colonization
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 subjects per group will be randomized to receive study drug or saline followed by a wash
      out period and cross-over to the other treatment, three times daily for 4 days. Nasal swab
      will be done at baseline and after both study treatment and saline treatment for assessment
      of airway colonization.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 17, 2017</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal bacterial colonization</measure>
    <time_frame>Day 5 of placebo or Tham intervention</time_frame>
    <description>Culture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment questionnaire</measure>
    <time_frame>Day 5 of placebo or Tham intervention</time_frame>
    <description>Questionnaire for local side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tham</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tham</intervention_name>
    <description>alkalinizer</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy subjects:

        Inclusion Criteria:

          -  16 subjects, aged 16-80, clinically stable with no significant changes in health
             status for 14 days prior to Day 1, written informed consent obtained fom subject.

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Use of any investigational drug and/or participated in any interventional clinical
             trial within 28 days prior to screening, smoked in the last 6 months.

        CF subjects:

        Inclusion Criteria:

          -  FEV1% &gt;35%, O2 saturation &gt;90% on room air, clinically stable with no significant
             changes in health status for 14 days prior to Day 1, written informed consent
             obtained from subject.

        Exclusion Criteria:

          -  Same as for healthy subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Launspach, RN</last_name>
    <phone>319-356-2047</phone>
    <email>janice-launspach@uiowa.edu</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>March 1, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Lakshmi Durairaj</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
